For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

The investment narrative surrounding Hims & Hers Health, Inc. presents a complex puzzle. On one hand, institutional money is flowing in and the company i ...

A stark divergence is emerging at telehealth provider Hims & Hers. The company is aggressively pursuing operational expansion, yet this stands in sharp c ...

Undeterred by domestic regulatory concerns, Hims & Hers is actively executing its global strategy. On December 10, the company launched its comprehensive weight-loss program in the United Kingdom, ...

HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

Analysts are largely maintaining a "Hold" stance for now. The consensus average price target of $44.90 implies potential upside, but experts appear to be taking a wait-and-see approach. The key ...

Goldman Sachs Group Inc, SPDR® S&P 500® ETF Trust, MGM Resorts International, International Business Machines. Read 's Market Analysis on Investing.com ...

Kristin is an executive search partner at Koller Search and based in Los Angeles. She partners with high-growth, venture ...

HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.